No Data
Pasithea Therapeutics Announces The Completion Of Long-Term Chronic Toxicity Studies In Both Rats And Dogs With Its Lead Candidate PAS-004, Currently Being Investigated In A Phase 1 Clinical Trial In Advanced Cancer Patients
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to Its Scientific Advisory Board
Express News | Pasithea Therapeutics Announces Appointment of DR. Rebecca Brown to Its Scientific Advisory Board
Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
10-Q: Q2 2024 Earnings Report
Pasithea Therapeutics Announces An Independent Safety Review Committee Completes Safety Review Of Data From First Dose Cohort In Phase 1 Trial Of PAS-004
No Data
No Data
